

Supplemental materials.




Figure S1: Correlation between SARS-CoV-2 spike protein immunoglobulin G titers and age, or duration from the second vaccination to T1/T2. (A) Correlation between SARS-CoV-2 spike protein immunoglobulin G (S-IgG) titers and age in all participants 1–5 weeks after the second vaccination (T1) ($n=58$). (B) Correlation between S-IgG titers and duration from the second vaccination to T1 in all participants ($n = 58$). (C) Correlation between S-IgG titers and age in all participants approximately 6 months after the second vaccination (T2) ($n = 50$). (D) Correlation between S-IgG titers and duration from the second vaccination to T2 in all participants ($n = 50$).

Supplemental Table S1

Details of molecular response change from pre-vaccination to T2			Molecular response	
Participant's number	TKI	TKI dose (mg)	pre-vaccination	T2
#3	Dasatinib	70	non-MMR	MMR
#14	Dasatinib	70	MMR	MR4.0
#26	Nilotinib	600	MR4.0	MR4.5
#32	Nilotinib	600	MMR	MR4.0
#39	Imatinib	100	Undetectable	MR4.0

Abbreviations: TKI: tyrosine kinase inhibitor, MMR: major molecular response, T2: around 6 months after 2nd VC,